Figure 2. SMIP-016 and SMIP-016^GV show similar methods of direct cytotoxicity. (A) SMIP-016 and SMIP-016^GV show comparable levels of direct cytotoxicity in primary CLL B cells (n = 11) (p = 0.0708). (B) SMIP-016 and SMIP-016^GV kills cells in a Type I antibody-like manner. Microscopy images of CLL B cells (i) untreated (ii) Type II antibody (iii) SMIP-016 or (iv) SMIP-016^GV for 16 h (n = 3). (C) Both SMIP-016 and SMIP-016^GV induced a similar pattern of tyrosine phosphorylation of cellular proteins at 65 kDa. CLL cells were treated with 5μg/mL of SMIP-016 or SMIP-016^GV with anti-Fc cross-linking antibody in PBS for 10 min and phospho tyrosine proteins were detected by western blot analysis using anti-phosphotyrosine antibody 4G10 (n = 6). (D) SMIP-016 and SMIP-016^GV do not initiate complement dependent cytotoxicity in CLL B cells (n = 6).